fbpx
November 22, 2022

FDA Alert: ‘Substantial’ Hypocalcemia Risk with Prolia Use FDA Alert: ‘Substantial’ Hypocalcemia Risk with Prolia Use

The US Food and Drug Administration (FDA) issued an alert today that cited preliminary evidence for a “substantial risk” for severe and symptomatic hypocalcemia and serious […]
November 17, 2022

Tenapanor Scores FDA Advisory Committee Endorsement Tenapanor Scores FDA Advisory Committee Endorsement

Tenapanor, a novel agent seeking US Food and Drug Administration (FDA) approval for treating hyperphosphatemia in patients on dialysis, received endorsement from an agency advisory committee […]
November 16, 2022

Balanced Crystalloid Fluids Surpass Saline for Kidney Transplant Balanced Crystalloid Fluids Surpass Saline for Kidney Transplant

Dr Michael G. Collins ORLANDO, Florida — Using a low-chloride, balanced crystalloid solution for all intravenous (IV) fluids received by patients who received a deceased donor kidney […]
November 9, 2022

New Economic Study: Dapagliflozin Cost-Effective in Kidney Disease New Economic Study: Dapagliflozin Cost-Effective in Kidney Disease

The sodium-glucose cotransporter-2 (SGLT2) inhibitor dapagliflozin (Farxiga) — despite the cost of the drug being high — is still a cost-effective option compared with standard of care […]
November 5, 2022

Study Sheds New Light on RAS Inhibitors’ Role for Advanced CKD Study Sheds New Light on RAS Inhibitors’ Role for Advanced CKD

ORLANDO, Florida — Treatment with a renin-angiotensin system (RAS) inhibitor is widely accepted as standard practice for slowing progression of chronic kidney disease (CKD), but data […]
November 4, 2022

Moving the Needle: SGLT2 Inhibitor Role for Kidney Disease Moving the Needle: SGLT2 Inhibitor Role for Kidney Disease

ORLANDO, Florida — The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin (Jardiance) significantly slowed progression of renal dysfunction or death from cardiovascular causes among patients with chronic […]
October 31, 2022

Third of Nondialysis Kidney Disease Patients Have Severe Symptoms Third of Nondialysis Kidney Disease Patients Have Severe Symptoms

Researchers have identified two distinct symptom trajectories in nondialysis dependent patients with moderate to severe, stage 3 to 5, chronic kidney disease (CKD). Close to a […]
October 27, 2022

Daprodustat Gets FDA AdComm Nod for Adults With CKD on Dialysis Daprodustat Gets FDA AdComm Nod for Adults With CKD on Dialysis

Daprodustat, an oral agent that boosts hemoglobin levels, became the first member of the hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) class to receive support from a […]
October 25, 2022

Oral Steroid Safely Treats IgA Nephropathy: Trial Published Oral Steroid Safely Treats IgA Nephropathy: Trial Published

Patients with immunoglobulin A (IgA) nephropathy showed clinically meaningful improvements in several measures of renal function after 9 months of treatment with a delayed-release formulation of […]
google.com, pub-5711488453051849, DIRECT, f08c47fec0942fa0